Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230023/S011

GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)

W. L. Gore & Associates, Inc. · Decision date Apr 9, 2026

FDA DECISIONP230023/S011

What did the FDA decide?

FDA records P230023/S011 as a supplement to PMA P230023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 9, 2026.

FDA approval order statement

implementation of an alternative UV curing system for assembly of components of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE) delivery system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230023/S011
Regulatory pathway
PMA supplement
Product code
QZK
Decision code
OK30
Decision date
Apr 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions.

Product code
QZK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230023/S009 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

  2. P230023/S010 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

  3. P230023/S011 received

    Application receipt date recorded by FDA.

  4. P230023/S011 · FDA decision

    30-Day Notice

  5. P230023/S012 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

Timeline entries are records held by MedtechLedger for P230023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230023

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA supplementSep 9, 2025FDA
W. L. Gore & Associates, Inc.PMA supplementJan 15, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementJul 1, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3450 W. Kiltie Ln., Flagstaff, AZ, 86005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records